RxDoctor Payments Data

Jana van Wie, MD

Family Medicine · Grand Island, NENPI 1720062458

Payments from drug & device makers

$2,564in general payments, 2019–2025

Across 160 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$596
  • Lilly USA, LLC$235
  • Pfizer$151
  • Novo Nordisk$139
  • Mallinckrodt Hospital Products Inc.$133
  • Amgen$108
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$2,54599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,564 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$53,444
Medicare patients
173
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin54$59,614
OzempicSemaglutide52$48,137
EliquisApixaban48$38,732
MounjaroTirzepatide31$36,044
LinzessLinaclotide36$22,456
FarxigaDapagliflozin Propanediol16$21,087
JanuviaSitagliptin Phosphate23$20,732
RybelsusSemaglutide14$15,343
XareltoRivaroxaban25$15,293
Tresiba Flextouch U-200Insulin Degludec13$11,330
AbrysvoRsv Vacc, Pref A And Pref B/Pf35$10,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,486
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen162$7,063
ShingrixVaricella-Zoster Ge/As01b/Pf29$6,073
Janumet XrSitagliptin Phos/Metformin Hcl14$5,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$139$63,48066 claims
PfizerEliquis, Abrysvo$151$49,23983 claims
Lilly USA, LLCMounjaro$235$36,04431 claims
MerckJanuvia, Janumet Xr$24$25,91337 claims
AbbVieLinzess$596$22,45636 claims
AstraZenecaFarxiga$75$21,08716 claims
Johnson & JohnsonXarelto$37$15,29325 claims
GSKTrelegy Ellipta, Shingrix$42$13,55941 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →